2-Bromo-3-methoxypyridine | CAS:24100-18-3

We serve 2-Bromo-3-methoxypyridine CAS:24100-18-3 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
2-Bromo-3-methoxypyridine

Chemical Name:2-Bromo-3-methoxypyridine
CAS.NO:24100-18-3
Synonyms:2-BroMo-3-Methoxypyridine;
Molecular Formula:C6H6BrNO
Molecular Weight:188.02200
 
Physical and Chemical Properties:
Melting point:45-49oC;
Flash point:63oC;
 
Specification:
Appearance:Off-white solid
Purity:≥99.0%
 
Packing:25 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:Intermediate for organic synthesis



Contact us for information like 2-Bromo-3-methoxypyridine chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,2-BroMo-3-Methoxypyridine physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,2-BroMo-3-Methoxypyridine Use and application,2-BroMo-3-Methoxypyridine technical grade,usp/ep/jp grade.


Related News: Like other countries in Southeast Asia, Indonesia depends heavily on Chinese tourism. On Thursday alone, 10,000 Chinese tourists canceled their trips to Bali, according to one industry association.2-Fluoro-3-iodo-5-methylpyridine manufacturer Our previous work with Retrogenix validated their technology as a uniquely powerful approach for antibody target deconvolution, and we look forward to working with Retrogenix to enhance our growing pipeline of antibody candidates.”2-Bromo-5-chloroanisole supplier In order to find answers to these questions, our staff in the development department set about conducting a series of experiments.1-(2,3-difluorophenyl)ethanone vendor In order to find answers to these questions, our staff in the development department set about conducting a series of experiments.China’s pharmaceutical CMO market has recently maintained a growth rate of more than 10%. From the perspective of market structure, the average growth rate of clinical production is 9.5%, while the average growth rate of commercial production will reach 18.7%.